Evidence map›Paper›PMID 39861771›Full record

ReviewPharmaceutics2025

What Is the Optimal Geometry of Dissolving Microneedle Arrays? A Literature Review.

Maira Visscher, Henderik W Frijlink, Wouter L J Hinrichs

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maira VisscherDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.ORCID 0000-0002-6766-1570
Henderik W FrijlinkDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.ORCID 0000-0001-7901-8198
Wouter L J HinrichsDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.ORCID 0000-0002-1481-2769

Funding

Northern Netherlands Provinces alliance OPSNN0325
6 · The paper itself

Abstract

The application of dissolving microneedle arrays (DMNAs) is an emerging trend in drug and vaccine delivery as an alternative for hypodermic needles or other less convenient drug administration methods. The major benefits include, amongst others, that no trained healthcare personnel is required and that the recipient experiences hardly any pain during administration. However, for a successful drug or vaccine delivery from the DMNA, the microneedles should be inserted intact into the skin. A successful penetration into the upper skin layers may be challenging because of the elastic nature of the skin; therefore, a minimum insertion force is required to overcome the total resistance force of the skin. In addition, the microneedles need to stay intact, which requires a certain mechanical strength, and be able to resist the required insertion force. In addition to the type of material with which the DMNAs are produced, the geometry of the DMNAs will also have a profound effect, not only on the mechanical strength but also on the number of insertions and penetration depth into the skin. In this review, the effects of shape, aspect ratio, length, width of the base, tip diameter and angle, and spacing of DMNAs on the aforementioned effect parameters were evaluated to answer the following question: 'What is the optimal geometry of dissolving microneedle arrays?'.

Indexed as

designdissolving microneedlesdrug delivery systemgeometryintradermalmechanical strengthoptimizationskin insertionskin penetrationtransdermal

Identifiers

PMID39861771
PMCPMC11769129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.